Brief: Ultimovacs: Universal Cancer Vaccine To Be Tested In Phase II Trial

Zelluna ASA

13/12/2019 09:35

Dec 13 (Reuters) - Ultimovacs ASA  ULTIMO.OL :
    * UNIVERSAL CANCER VACCINE UV1 WILL BE INVESTIGATED IN
RANDOMIZED,
MULTI-CENTER PHASE II TRIAL IN MESOTHELIOMA
    * BRISTOL-MYERS SQUIBB  AND CO ENTERED INTO AGREEMENTS WITH
OUS TO
SUPPORT PREPARATIONS AND EXECUTION OF TRIAL
    * STUDY IS PLANNED TO BE CONDUCTED AT 6 HOSPITALS IN 5
COUNTRIES
    * PRIMARY ENDPOINT OF TRIAL IS PROGRESSION-FREE SURVIVAL
(PFS) AND
PFS READ-OUT IS EXPECTED MID-2022
    * WILL COVER COSTS ASSOCIATED WITH ITS PARTICIPATION IN
STUDY FROM
EXISTING FUNDS
    * IN Q1 2020, CO EXPECTS TO INCLUDE FIRST PATIENT IN
RANDOMIZED
TRIAL IN MALIGNANT MELANOMA WHERE UV1 IS COMBINED WITH NIVOLUMAB
AND IPILIMUMAB

Source text for Eikon:  ID:nObi51D8Ra 
Further company coverage:  ULTIMO.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))